New hope for tough stomach cancers: experimental combo therapy enters testing
NCT ID NCT07356466
Summary
This study is testing whether adding two newer drugs (pucotenlimab and lenvatinib) to a standard chemotherapy regimen (SOX) works better for advanced stomach cancer than the standard chemotherapy alone. It will involve 100 adults with a specific type of advanced stomach cancer who haven't had prior treatment for their advanced disease. The main goal is to see if more patients' tumors shrink with the new combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC (STOMACH) CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
Conditions
Explore the condition pages connected to this study.